Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTx-COVAB36 in Healthy Volunteers
NCT05351437Phase 1Completed
- Sponsor
- Memo Therapeutics AG
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing MTx-COVAB36 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events. Started Apr 2022; status: completed.
02
Drugs
MTX-COVAB36
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05351437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351437.